These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 23294275)

  • 21. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
    Kubitza D; Becka M; Mueck W; Zuehlsdorf M
    J Clin Pharmacol; 2006 Sep; 46(9):981-90. PubMed ID: 16920892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
    Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects.
    Kubitza D; Becka M; Roth A; Mueck W
    J Int Med Res; 2012; 40(5):1688-707. PubMed ID: 23206451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients.
    Esmaeili T; Rezaee M; Abdar Esfahani M; Davoudian A; Omidfar D; Rezaee S
    J Clin Pharm Ther; 2022 Aug; 47(8):1284-1292. PubMed ID: 35504629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
    Gheorghiade M; Thyssen A; Zolynas R; Nadar VK; Greenberg BH; Mehra M; Sun X; Tian H; Plotnikov AN; Burton P
    J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.
    Kubitza D; Becka M; Mueck W; Zuehlsdorf M
    Br J Clin Pharmacol; 2007 Apr; 63(4):469-76. PubMed ID: 17100983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
    Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
    J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
    Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
    J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
    Kubitza D; Mueck W; Becka M
    Drug Saf; 2008; 31(1):67-77. PubMed ID: 18095747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban: an oral direct inhibitor of factor Xa.
    Gulseth MP; Michaud J; Nutescu EA
    Am J Health Syst Pharm; 2008 Aug; 65(16):1520-9. PubMed ID: 18693206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W; Kubitza D; Becka M
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Misselwitz F
    Nat Rev Drug Discov; 2011 Jan; 10(1):61-75. PubMed ID: 21164526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
    Kubitza D; Becka M; Zuehlsdorf M; Mueck W
    J Clin Pharmacol; 2006 May; 46(5):549-58. PubMed ID: 16638738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.